Beth Israel Deaconess Medical Center Brighton, Massachusetts
Andy Silva-Santisteban, MD1, Ankit Chhoda, MD2, Maria Hernandez Woodbine, MD2, Loren Rabinowitz, MD2, Alyssa Grimshaw, MBA3, James J. Farrell, MD4, Mandeep Sawhney, MD, MS2 1Beth Israel Deaconess Medical Center, Brighton, MA; 2Beth Israel Deaconess Medical Center, Boston, MA; 3Yale University Libraries, West Haven, CT; 4Yale School of Medicine, New Haven, CT
Introduction: Inclusion of underrepresented groups in cancer research is a priority. Better characterization of pancreatic cancer screening study participants is needed before results can be generalized. We sought to assess sex, racial, and ethnic make-up of high-risk individuals (HRIs) included in pancreatic cancer surveillance studies.
Methods: A systematic search of Cochrane Library, Ovid Embase, Google Scholar, Ovid Medline, PubMed, Scopus, and Web of Science Core Collection from inception to 2022 was conducted. Original studies on pancreatic cancer screening were identified and assessed for reporting and inclusion on race, ethnicity, sex, and age. The pooled proportions of study participants for these characteristics were calculated and compared with population-based benchmarks.
Results: A total of 26 of 27 studies were included in the meta-analysis. Information on participant sex was reported by (26), race (12), and ethnicity (8) of studies. Of the included studies, 14 were from US, 2 from Canada, 5 from Europe (1 Italy, 2 Netherlands, 1 Denmark, 1 Sweden), 3 from Asia (Japan, Taiwan, Israel), 1 from Argentina and 1 from Australia.
Race was reported by 9 of 14 US studies. Almost all study participants were white with a pooled prevalence of 90.0% (95% CI:84.1%-95.8%). Ethnicity was reported by only 6 of 14 US studies. The pooled prevalence of non-Latino was 96.7% (95% CI:92.7%-100%). Proportion of study participants by race and ethnicity (vs. proportion of race in the US general population) was as follows: White 92.1% (58%), Black 3.3% (12.1%), American Indian/Alaska Native 0% (0.7%), Asian 1.1% (5.9%) and Latino 3.2% (18.7%) which shows non-white racial groups substantially underrepresented (Fig 1). There was no trend in improved race and ethnicity reporting with year of study publication (p=0.6). Of the 4952 HRIs in the 26 studies, pooled prevalence of females was 63.2% (95% CI:59.9%-66.6%). Female representation in the US was significantly higher compared to studies from other countries (65.9% vs 58.5%, p=.00). All studies had majority of female participants except Denmark (49.2%), Argentina (48.7%) and Israel (43%) studies. There was no improvement in participant sex reporting with ascending study publication year (p=0.5). When reported, mean or median participant age was < 60 years.
Discussion: Substantial disparities in race, ethnicity, sex, and age reporting and inclusion in pancreatic cancer studies were noted, underscoring the need for efforts to improve diversity in future studies.
Figure: Figure 1: A) Forest plot showing proportion of White study participants in all studies compared with studies from the United States (US) only. B) Forest plot showing proportion on non-Hispanic participants in all studies compared with studies from the United States (US) only. C) Proportion of study participants by race and ethnicity compared with their proportions in the general United States population.
Disclosures:
Andy Silva-Santisteban indicated no relevant financial relationships.
Ankit Chhoda indicated no relevant financial relationships.
Maria Hernandez Woodbine indicated no relevant financial relationships.
Loren Rabinowitz indicated no relevant financial relationships.
Alyssa Grimshaw indicated no relevant financial relationships.
James J. Farrell indicated no relevant financial relationships.
Mandeep Sawhney: Allurion – Stock Options. Immunovia Inc. – Consultant. Marlborough, MA – Consultant.
Andy Silva-Santisteban, MD1, Ankit Chhoda, MD2, Maria Hernandez Woodbine, MD2, Loren Rabinowitz, MD2, Alyssa Grimshaw, MBA3, James J. Farrell, MD4, Mandeep Sawhney, MD, MS2. P2845 - Disparities in Race, Ethnicity, Sex, and Age Inclusion in Pancreatic Cancer Screening Studies: A Systematic Review and Meta-Analysis, ACG 2023 Annual Scientific Meeting Abstracts. Vancouver, BC, Canada: American College of Gastroenterology.
